Effectiveness of postoperative chemotherapy for para-aortic lymph node metastasis of endometrial cancer

被引:10
作者
Takeshima, Nobuhiro [1 ]
Umayahara, Kenji [1 ]
Fujiwara, Kiyoshi [1 ]
Hirai, Yasuo [1 ]
Takizawa, Ken [1 ]
Hasumi, Katsuhiko [1 ]
机构
[1] Canc Inst Hosp, Dept Gynecol, Koto Ku, Tokyo 1358550, Japan
关键词
endometrial cancer; lymph node; metastasis; chemotherapy;
D O I
10.1016/j.ygyno.2005.12.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To examine the effectiveness of postoperative chemotherapy for para-aortic lymph node (PAN) metastasis in patients with endometrial cancer. Methods. Among 350 clinical stage I-II endometrial cancer patients who underwent systemic pelvic and para-aortic lymphadenectomy during the period 1995 through 2002,26 patients were identified with PAN metastasis. Of these patients, nine had only one positive PAN and 17 had two or more positive PANs (mean 4.9, range 1-22). All patients were treated postoperatively with a single chemotherapy regimen consisting of ifosfamide, epiadriamycin, and cisplatin scheduled for 5 cycles. Median (range) follow-up for surviving patients was 85 (38-119) months. Treatment outcome, including disease-free survival relative to the number of positive PANs, was investigated. Results. Among the 26 patients with PAN involvement, four developed recurrence. Three of the four patients had 10 or more positive PANs. Estimated 5-year disease-free survival rates were 89% for patients with one positive PAN, 82% for those with two or more positive PANs, and 85% for all patients. No significant difference was identified between the first two groups (P = 0.6543). Conclusions. Postoperative chemotherapy can yield a favorable outcome in endometrial cancer patients with PAN metastasis, even those with multiple positive nodes. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:214 / 217
页数:4
相关论文
共 21 条
[1]  
AALDERS J, 1980, OBSTET GYNECOL, V56, P419
[2]  
[Anonymous], P AM SOC CLIN ONCOLO
[3]   Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial [J].
Aoki, Y ;
Watanabe, M ;
Amikura, T ;
Obata, H ;
Sekine, M ;
Yahata, T ;
Fujita, K ;
Tanaka, K .
GYNECOLOGIC ONCOLOGY, 2004, 94 (02) :333-339
[4]   Stage III endometrial cancer: Analysis of prognostic factors and failure patterns after adjuvant chemotherapy [J].
Aoki, Y ;
Kase, H ;
Watanabe, M ;
Sato, T ;
Kurata, H ;
Tanaka, K .
GYNECOLOGIC ONCOLOGY, 2001, 83 (01) :1-5
[5]   Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma:: multicentre randomised trial [J].
Creutzberg, CL ;
van Putten, WLJ ;
Koper, PCM ;
Lybeert, MLM ;
Jobsen, JJ ;
Wárlám-Rodenhuis, CC ;
De Winter, KAJ ;
Lutgens, LCHW ;
van den Bergh, ACM ;
van de Steen-Banasik, E ;
Beerman, H ;
van Lent, M .
LANCET, 2000, 355 (9213) :1404-1411
[6]   Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer [J].
Greven, K ;
Winter, K ;
Underhill, K ;
Fontenesci, J ;
Cooper, J ;
Burke, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (01) :168-173
[7]  
GREVEN KM, 1993, CANCER-AM CANCER SOC, V71, P3697, DOI 10.1002/1097-0142(19930601)71:11<3697::AID-CNCR2820711137>3.0.CO
[8]  
2-U
[9]   SURVIVAL IN PATIENTS WITH PARAAORTIC LYMPH-NODE METASTASES FROM ENDOMETRIAL ADENOCARCINOMA CLINICALLY LIMITED TO THE UTERUS [J].
HICKS, ML ;
PIVER, MS ;
PURETZ, JL ;
HEMPLING, RE ;
BAKER, TR ;
MCAULEY, M ;
WALSH, DL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (04) :607-611
[10]  
LAUNCHBURY AP, 1993, CANCER TREAT REV, V19, P197